Strongbridge Biopharma: Commercial stage, focused on rare diseases w significant unmet needs. Endocrine franchise includes RECORLEV™, cortisol synthesis inhibitor in Ph 3 for endogenous Cushing's syndrome, and veldoreotide, next-gen somatostatin analog for acromegaly. Neuromuscular franchise includes KEVEYIS® approved for primary periodic paralysis. Company sold NA rights for MACRILEN™ to Novo Nordisk for $145 m upfront and tiered royalties in Oct 2018. RECORLEV Ph 3 data (LOGICS trial) exp end of Q1 2020; NDA submission exp Q3 2020.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
USA
Clinical Stage
Marketed
Disease Space
Central Nervous System, Rare Disease
Finance
Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
<100MM
Website:
Profiles:
Address:
900 Northbrook Dr #200
Feasterville Trevose, PA 19053
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout Management Access: SF 2020

San Francisco, CA, United States, January 13 – January 16, 2020

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.